How Will the Market React to Allogene Therapeutics Inc (ALLO) Stock Getting a Bullish Rating

Allogene Therapeutics Inc (ALLO) stock has gained 20.00% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Allogene Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ALLO!

See Full ALLO Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With ALLO Stock Today?

Allogene Therapeutics Inc (ALLO) stock is up 6.58% while the S&P 500 is lower by -0.1% as of 10:15 AM on Friday, Nov 17. ALLO has risen $0.18 from the previous closing price of $2.81 on volume of 174,116 shares. Over the past year the S&P 500 has gained 13.77% while ALLO is lower by -69.04%. ALLO lost -$2.24 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Allogene Therapeutics Inc click here.

More About Allogene Therapeutics Inc

Allogene Therapeutics Inc is a United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies. Click Here to get the full Stock Report for Allogene Therapeutics Inc stock.